Kristian F. Humer's most recent trade in 4D Molecular Therapeutics Inc was a trade of 480,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | Kristian F. Humer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2025 | 480,000 | 480,000 | - | - | Stock Option (Right to Buy) | |
| Sensei Biotherapeutics Inc | Kristian F. Humer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Foghorn Therapeutics Inc | Kristian F. Humer | Chief Financial Officer | 22 Jan 2025 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | ||
| Sensei Biotherapeutics Inc | Kristian F. Humer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Foghorn Therapeutics Inc | Kristian F. Humer | Chief Financial Officer | 16 Apr 2024 | 275,000 | 275,000 | - | - | Stock Option (Right to buy) |